The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InThe European Commission has granted marketing authorization for Merck’s ENFLONSIA (clesrovimab), a monoclonal antibody designed to protect infants from Respiratory Syncytial Virus (RSV). This drug stands out as the first and only RSV preventive in the EU that does not require weight-based dosing, simplifying clinical administration for newborns. A single dose provides protection for up to 5 months, effectively covering a typical RSV season. The approval was based on clinical trial data demonstrating a significant reduction in RSV-related hospitalizations and disease incidence. This regulatory milestone is expected to strengthen Merck’s competitive position within the European healthcare market. The authorization addresses a major cause of infant respiratory illness, providing a streamlined solution for healthcare providers.